Idarucizumab for the treatment of dabigatran-related nephropathy

4Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Anticoagulant-related nephropathy (ARN) is a clinical syndrome of acute kidney injury in patients taking vitamin K antagonists or direct oral anticoagulants. It is associated with increased mortality and there is no specific treatment. We report the case of a 78-year-old man on dabigatran who developed macroscopic haematuria and acute kidney injury 2 weeks after mitral valve repair, reaching a peak creatinine of 415 µmol/L from a normal baseline, which was successfully treated with one course of idarucizumab. This case illustrates the efficacy of an anticoagulant reversal agent for the treatment of ARN.

Cite

CITATION STYLE

APA

Alsamarrai, A., Eaddy, N., & Curry, E. (2021). Idarucizumab for the treatment of dabigatran-related nephropathy. Clinical Kidney Journal, 14(2), 710–711. https://doi.org/10.1093/ckj/sfaa030

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free